Abstract
The tributyrin lipid emulsion was proved to be able to bind to low-density lipoprotein (LDL) in vitro. The aim of this study was to investigate the pharmacokinetics of the emulsion in vivo and the cellular activity in vitro. The pharmacokinetics of tributyrin and its metabolite, butyrate, was evaluated in male Wistar rats after administration with pure tributyrin or tributyrin emulsion. After oral administration, maximal plasma concentration (Cmax), time to reach maximal plasma concentration (Tmax), and elimination half-life (T1/2) of butyrate were 87.6 μM and 25.3 and 63.0 min, respectively, for the pure tributyrin compared with 1344.5 μM and 8.5 and 19.8 min for the 10% (v/v) tributyrin emulsion. Cmax and mean residence time of tributyrin were 2.74 μM and 87.9 min and 4.2 μM and 132.0 min for pure tributyrin and 10% emulsion, respectively. The bioavailabilities of the pure tributyrin versus tributyrin emulsion were 15.3 versus 65.7% and 34.9 versus 64.5% calculated from butyrate and tributyrin, respectively. After the rats were treated with 17α-ethynylestradiol (an LDL receptor up-regulator), the distribution volumes calculated from both butyrate and tributyrin were significantly increased after oral administration or infusion of the 10% tributyrin emulsion. The increased distribution volume after coadministration with a LDL receptor up-regulator suggested the increased uptake of tributyrin/butyrate by tissues with increased expression of LDL receptors. The selective uptake of the emulsion by the cellular LDL receptors was further confirmed by testing the cellular viability in the presence of competing LDL. The viable cells can reach 92% of control at IC50 in Caco-2 and 77% in HepG2 incubated with emulsion in the presence of LDL.
Footnotes
-
doi:10.1124/jpet.105.090464.
-
ABBREVIATIONS: LDL, low-density lipoprotein; FITC, fluorescein isothiocyanate; apoB and apoE, apolipoproteins B and E, respectively; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; AUC, area under the curve; CL, total clearance; TAE, Tris acetate-EDTA; TE, Tris-EDTA; DABCO, 2.5% 1,4-diazabicyclo[2.2.2] octane; BSA, bovine serum albumin; PBS, phosphate-buffered saline.
- Received June 24, 2005.
- Accepted September 16, 2005.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|